Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

8.865
+0.1551.78%
Volume:95.91M
Turnover:839.32M
Market Cap:102.14B
PE:22.32
High:8.890
Open:8.580
Low:8.520
Close:8.710
52wk High:10.720
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:0.83
T/O Rate:0.83%
Dividend:0.34
Dividend Rate:3.80%
EPS(LYR):0.397
ROE:20.90%
ROA:10.70%
PB:2.32
PE(LYR):22.32
PS:2.79

Loading ...

CSPC Pharmaceutical - Kn026 and Hb1801 Combination Previously Granted Breakthrough Therapy Designation by Nmpa

THOMSON REUTERS
·
Aug 18

CSPC Pharmaceutical - Nda Indication: First-Line Treatment of Unresectable or Metastatic Her2-Positive Breast Cancer

THOMSON REUTERS
·
Aug 18

CSPC Innovation Posts RMB 1.26 Billion H1 Net Profit on RMB 3.24 Billion Revenue

Reuters
·
Aug 17

CSPC Innovation Pharmaceutical H1 Net Profit 1.3 Billion Yuan

Reuters
·
Aug 17

Movement Alert|CSPC PHARMA Rises 3.22% in Regular Trading, Innovative Pharma Sector Strengthens as AstraZeneca Payments Confirmed

Market Focus
·
Aug 17

CSPC Pharmaceutical Group Stock Rallies 2.0% in Hong Kong, Outperforms Competitors

Dow Jones
·
Aug 13

Earning Preview: CSPC PHARMA Q2 revenue expected to increase by 25.43%, institutional views are bullish

Earnings Agent
·
Aug 13

Movement Alert|CSPC PHARMA Rises 3.57% in Regular Trading, AstraZeneca siRNA Collaboration $30 Million Upfront Payment Received

Market Focus
·
Aug 13

CSPC Pharmaceutical Changes Trustee for 2018 Share Award Scheme to BOCI Trustee Hong Kong

Reuters
·
Aug 12

CSPC Pharmaceutical Group Announces Change in Trustee for 2018 Share Award Scheme

Stock News
·
Aug 12

CSPC Pharmaceutical Receives USD 30 Million Upfront Payment from AstraZeneca Under siRNA Pact

Reuters
·
Aug 12

CSPC Pharmaceutical - Receives US$30 Mln Upfront Payment from AstraZeneca on Aug 12 2026 Under Collaboration Agreement

THOMSON REUTERS
·
Aug 12

CSPC Pharma Starts Phase 1 Trial of CAR-T Drug for Relapsed, Refractory Lupus

MT Newswires Live
·
Aug 12

CSPC Pharma's SYS 6063 Trial for Lupus Clears First Site in China

Stock News
·
Aug 11

CSPC Pharmaceutical - Pharma Initiates Phase I Trial of Sys6063 for Relapsed, Refractory Sle in China

THOMSON REUTERS
·
Aug 11

Movement Alert|CSPC PHARMA Rises 3.19% in Regular Trading, Monkeypox mRNA Vaccine Receives FDA Clinical Trial Approval

Market Focus
·
Aug 11

CSPC Pharmaceutical's Mpox Vaccine Candidate Gets Trial Approval from US FDA

MT Newswires Live
·
Aug 10

CSPC Pharma Sets 20 Aug 2026 Board Meeting to Approve 1H 2026 Interim Results

Bulletin Express
·
Aug 10

CSPC Pharma (01093) Receives FDA Clearance for US Clinical Trial of Monkeypox mRNA Vaccine

Stock News
·
Aug 10

CSPC Says FDA Clears US Clinical Trial for SYS 6037 Mpox mRNA Vaccine

Reuters
·
Aug 10